drugset / Trial / NCT01452529

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT01452529

Phase 3 Completed 905 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their current stable analgesic regimen

Timeline

Start
2011-10
Primary completion
2013-09
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocodone Unknown

Indications